ADOCIA announces patenting stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone® platform

Adocia Logo

Advancing Mealtime Insulin Therapy:
Phase 3 Results for BC Lispro in Type 2 Diabetes

Tuesday, June 16, 2026 | 10:00 AM ET / 4:00 PM CET

Click Here to Register & Attend